- Home
- ELEV vs ORIS Comparison
ELEV vs ORIS Comparison
Compare ELEV & ORIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELEV
- ORIS
- Stock Information
- Founded
- ELEV 2019
- ORIS 2014
- Country
- ELEV United States
- ORIS China
- Employees
- ELEV N/A
- ORIS N/A
- Industry
- ELEV Biotechnology: Pharmaceutical Preparations
- ORIS Farming/Seeds/Milling
- Sector
- ELEV Health Care
- ORIS Consumer Staples
- Exchange
- ELEV Nasdaq
- ORIS Nasdaq
- Market Cap
- ELEV 18.1M
- ORIS 19.5M
- IPO Year
- ELEV 2021
- ORIS 2024
- Fundamental
- Price
- ELEV $0.32
- ORIS $0.87
- Analyst Decision
- ELEV Buy
- ORIS
- Analyst Count
- ELEV 6
- ORIS 0
- Target Price
- ELEV $2.94
- ORIS N/A
- AVG Volume (30 Days)
- ELEV 750.8K
- ORIS 974.4K
- Earning Date
- ELEV 08-05-2025
- ORIS 02-21-2025
- Dividend Yield
- ELEV N/A
- ORIS N/A
- EPS Growth
- ELEV N/A
- ORIS N/A
- EPS
- ELEV N/A
- ORIS 0.17
- Revenue
- ELEV N/A
- ORIS $15,014,000.00
- Revenue This Year
- ELEV N/A
- ORIS N/A
- Revenue Next Year
- ELEV N/A
- ORIS N/A
- P/E Ratio
- ELEV N/A
- ORIS $5.12
- Revenue Growth
- ELEV N/A
- ORIS N/A
- 52 Week Low
- ELEV $0.22
- ORIS $0.82
- 52 Week High
- ELEV $3.77
- ORIS $56.01
- Technical
- Relative Strength Index (RSI)
- ELEV 49.38
- ORIS N/A
- Support Level
- ELEV $0.29
- ORIS N/A
- Resistance Level
- ELEV $0.32
- ORIS N/A
- Average True Range (ATR)
- ELEV 0.02
- ORIS 0.00
- MACD
- ELEV 0.00
- ORIS 0.00
- Stochastic Oscillator
- ELEV 59.01
- ORIS 0.00
About ELEV Elevation Oncology Inc. Common stock
Elevation Oncology Inc is an oncology company focused on the development of selective cancer therapies to treat patients across a range of solid tumors with unmet medical needs. Its product candidate, EO-3021 (also known as SYSA1801 or CPO102), is an ADC comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) site-specifically conjugated with a cleavable linker to the cytotoxic monomethyl auristatin E (MMAE) payload. Claudin 18.2 is overexpressed in several types of cancers, including gastric, esophageal, pancreatic, ovarian and lungon.
About ORIS Oriental Rise Holdings Limited Ordinary Shares
Oriental Rise Holdings Ltd is an integrated supplier of tea products in China. It is principally engaged in the business of planting, cultivating, processing, and selling processed tea. The company currently produces and sells three categories of products: roughly processed white tea, roughly processed black tea, and refined tea. The company's business operations are vertically integrated, covering cultivation, processing of tea leaves, and the sale of tea products to tea business operators and end-user retail customers. Geographically, the company generates all of its revenue from its business in the People's Republic of China (the PRC).